AAAAAA
Results: 1-25/65
Authors:
KRAMER A
HOCHHAUS A
SAUSSELE S
REICHERT A
WILLER A
HEHLMANN R
Citation: A. Kramer et al., CYCLIN A1 IS PREDOMINANTLY EXPRESSED IN HEMATOLOGICAL MALIGNANCIES WITH MYELOID DIFFERENTIATION, Leukemia, 12(6), 1998, pp. 893-898
Authors:
REITER A
MARLEY SB
HOCHHAUS A
SOHAL J
RAANANI P
HEHLMANN R
GORDON MY
GOLDMAN JM
CROSS NCP
Citation: A. Reiter et al., BCR-ABL-POSITIVE PROGENITORS IN CHRONIC MYELOID-LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC REMISSION AFTER TREATMENT WITH INTERFERON-ALPHA, British Journal of Haematology, 102(5), 1998, pp. 1271-1278
Authors:
KRAMER A
HORNER S
WILLER A
HOCHHAUS A
HALLEK M
HEHLMANN R
Citation: A. Kramer et al., ADHESION TO FIBRONECTIN INDUCES G(1) S PHASE PROGRESSION IN NORMAL AND BCR/ABL-TRANSFORMED HEMATOPOIETIC-CELLS/, British Journal of Haematology, 102(1), 1998, pp. 30-30
Authors:
KRAMER R
HOCHHAUS A
SAUSSELE S
REICHERT A
WILLER A
HEHLMANN R
Citation: R. Kramer et al., CYCLIN A1 IS PREDOMINANTLY EXPRESSED IN HEMATOLOGICAL MALIGNANCIES WITH MYELOID DIFFERENTIATION, British Journal of Haematology, 102(1), 1998, pp. 30-30
Authors:
HOCHHAUS A
REICHERT A
SAUSSELE S
REITER A
EMIG H
HEHLMANN R
GOLDMAN JM
CROSS NCP
Citation: A. Hochhaus et al., MOLECULAR HETEROGENEITY IN COMPLETE CYTOGENETIC RESPONDERS ON INTERFERON-ALPHA THERAPY OF CML - LEVELS OF MINIMAL RESIDUAL DISEASE PREDICT RISK OF RELAPSE, British Journal of Haematology, 102(1), 1998, pp. 283-283
Authors:
WILLER A
KRAMER A
SAUSSELE S
HOCHHAUS A
SEIFARTH W
HEHLMANN R
Citation: A. Willer et al., METHYLATION OF THE ABL PROMOTER IN CHRONIC MYELOGENOUS LEUKEMIA (CML)CORRELATES WITH DISEASE PROGRESSION, British Journal of Haematology, 102(1), 1998, pp. 283-283
Authors:
HEHLMANN R
HOCHHAUS A
BERGER U
MUTH A
KOLB HJ
PFIRRMANN M
HASFORD J
Citation: R. Hehlmann et al., SURVIVAL AFTER ALLOGENOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA (CML) IS NOT INFLUENCED BY PRETRANSPLANT INTERFERON-ALPHA THERAPY, British Journal of Haematology, 102(1), 1998, pp. 317-317
Authors:
LENGFELDER E
HOCHHAUS A
KRONAWITTER U
HOCHE D
QUEISSER W
JAHNEDER M
BURKHARDT R
REITER A
ANSARI H
HEHLMANN R
Citation: E. Lengfelder et al., SHOULD A PLATELET LIMIT OF 600X10(9) 1 BE USED AS A DIAGNOSTIC CRITERION IN ESSENTIAL THROMBOCYTHEMIA - AN ANALYSIS OF THE NATURAL COURSE INCLUDING EARLY STAGES/, British Journal of Haematology, 100(1), 1998, pp. 15-23
Authors:
GALE RP
HEHLMANN R
ZHANG MJ
HASFORD J
GOLDMAN JM
HEIMPEL H
HOCHHAUS A
KLEIN JP
KOLB HJ
MCGLAVE PB
PASSWEG JR
ROWLINGS PA
SOBOCINSKI KA
HOROWITZ MM
Citation: Rp. Gale et al., SURVIVAL WITH BONE-MARROW TRANSPLANTATION VERSUS HYDROXYUREA OR INTERFERON FOR CHRONIC MYELOGENOUS LEUKEMIA, Blood, 91(5), 1998, pp. 1810-1819
Authors:
HOCHHAUS A
YAN XH
WILLER A
HEHLMANN R
GORDON MY
GOLDMAN JM
MELO JV
Citation: A. Hochhaus et al., EXPRESSION OF INTERFERON REGULATORY FACTOR (IRF) GENES AND RESPONSE TO INTERFERON-ALPHA IN CHRONIC MYELOID-LEUKEMIA, Leukemia, 11(7), 1997, pp. 933-939
Authors:
CARAPETI M
SOEDEBOBOK A
HOCHHAUS A
SILL H
TOUW IP
GOLDMAN JM
CROSS NCP
Citation: M. Carapeti et al., RARITY OF DOMINANT-NEGATIVE MUTATIONS OF THE G-CSF RECEPTOR IN PATIENTS WITH BLAST CRISIS OF CHRONIC MYELOID-LEUKEMIA OR DE-NOVO ACUTE-LEUKEMIA, Leukemia, 11(7), 1997, pp. 1005-1008
Authors:
HEHLMANN R
ANSARI H
HASFORD J
HEIMPEL H
HOSSFELD DK
KOLB HJ
LOFFLER H
PRALLE H
QUEISSER W
REITER A
HOCHHAUS A
Citation: R. Hehlmann et al., COMPARATIVE-ANALYSIS OF THE IMPACT OF RISK PROFILE AND OF DRUG-THERAPY ON SURVIVAL IN CML USING SOKAL-INDEX AND A NEW SCORE, British Journal of Haematology, 97(1), 1997, pp. 76-85
Authors:
REITER A
SKLADNY H
HOCHHAUS A
SEIFARTH W
HEIMPEL H
BARTRAM CR
CROSS NCP
HEHLMANN R
Citation: A. Reiter et al., MOLECULAR RESPONSE OF CML PATIENTS TREATED WITH INTERFERON-ALPHA MONITORED BY QUANTITATIVE SOUTHERN BLOT ANALYSIS, British Journal of Haematology, 97(1), 1997, pp. 86-93
Authors:
KRAMER A
HOCHHAUS A
SAUSSELE S
REICHERT A
WILLER A
HEHLMANN R
Citation: A. Kramer et al., CYCLIN A1, A NOVEL CYCLIN A-LIKE GENE, IS EXPRESSED IN NORMAL AND MALIGNANT HEMATOPOIETIC-CELLS, Blood, 90(10), 1997, pp. 3596-3596
Authors:
HASFORD J
PUOSI F
ANSARI H
HOCHHAUS A
HEHLMANN R
Citation: J. Hasford et al., ADVERSE REACTIONS OF INTERFERON-ALPHA (IFN-ALPHA) IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA, Blood, 90(10), 1997, pp. 3992-3992
Authors:
HOCHHAUS A
BERGER U
ANSARI H
HASFORD J
HEHLMANN R
Citation: A. Hochhaus et al., PROSPECTIVE COMPARATIVE-ANALYSIS OF ADVERSE-EFFECTS DURING THE TREATMENT OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE WITH INTERFERON-ALPHA, BUSULFAN AND HYDROXYUREA, Blood, 90(10), 1997, pp. 3997-3997
Authors:
KRAMER A
WILLER A
HOCHHAUS A
SAUSSELE S
HALLEK M
HEHLMANN R
Citation: A. Kramer et al., ADHESION TO FIBRONECTIN STIMULATES G(1) S PHASE PROGRESSION IN NORMALAND BCR/ABL-TRANSFORMED HEMATOPOIETIC-CELLS/, Blood, 90(10), 1997, pp. 4002-4002
Authors:
SCHULTHEIS B
HEISSIG B
SICK C
HOCHHAUS A
PASTERNAK G
HEHLMANN R
Citation: B. Schultheis et al., LONG-TERM CULTURED COLONY-FORMING CELLS FROM PERIPHERAL-BLOOD OF CML PATIENTS UNDER INTERFERON-ALPHA OR HYDROXYUREA THERAPY SHOW DIFFERENCES IN BCR-ABL-POSITIVITY, Blood, 90(10), 1997, pp. 4015-4015
Authors:
WILLER A
KRAMER A
SAUSSELE S
HOCHHAUS A
SEIFARTH W
HEHLMANN R
Citation: A. Willer et al., DISEASE PROGRESSION IN CHRONIC MYELOGENOUS LEUKEMIA (CML) IS LINKED TO METHYLATION OF THE ABL PROMOTER, Blood, 90(10), 1997, pp. 865-865
Authors:
SCHMIDT M
NAGEL S
PROBA J
HOCHHAUS A
WARING JF
ROSENBAUER F
EHNINGER G
HUHN D
WITTIG B
HEHLMANN R
HORAK I
NEUBAUER A
Citation: M. Schmidt et al., LACK OF INTERFERON CONSENSUS SEQUENCE BINDING-PROTEIN (ICSBP) TRANSCRIPTS IN HUMAN MYELOID LEUKEMIAS AND INDUCTION BY INTERFERON-ALPHA, Blood, 90(10), 1997, pp. 878-878
Authors:
HEHLMANN R
KOLB HJ
BERGER U
MUTH A
HOCHHAUS A
ANSARI H
Citation: R. Hehlmann et al., INFLUENCE OF PRETRANSPLANT TREATMENT ON SURVIVAL AFTER ALLOGENEOUS BONE-MARROW TRANSPLANTATION IN CML, Blood, 90(10), 1997, pp. 1005-1005
Authors:
HOCHHAUS A
HEHLMANN R
BARTRAM CR
HEIMPEL H
REITER A
BERGER U
ANSARI H
SKLADNY H
HEINZE B
HOSSFELD DK
Citation: A. Hochhaus et al., RANDOMIZED COMPARISON OF INTERFERON-ALPHA VS CHEMOTHERAPY IN PATIENTSWITH PHILADELPHIA-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA (CML), Blood, 90(10), 1997, pp. 2298-2298
Authors:
ALJEHANI F
HOCHHAUS A
SPENCER A
GOLDMAN JM
MELO JV
Citation: F. Aljehani et al., EXPRESSION OF THE LH2 GENE IN CHRONIC MYELOID-LEUKEMIA CELLS, Leukemia, 10(7), 1996, pp. 1122-1126
Authors:
HOCHHAUS A
CROSS NCP
GOLDMAN JM
Citation: A. Hochhaus et al., MONITORING OF RESIDUAL DISEASE IN CHRONIC MYELOGENOUS LEUKEMIA - METHODOLOGICAL APPROACHES AND CLINICAL ASPECTS - COMMENTS, Leukemia, 10(5), 1996, pp. 904-905
Authors:
LENGFELDER E
HOCHHAUS A
HEHLMANN R
Citation: E. Lengfelder et al., ESSENTIAL THROMBOCYTHEMIA - CURRENT OPINION IN DIAGNOSIS, CLINICAL COURSE, AND TREATMENT, Onkologie, 19(1), 1996, pp. 44-48